Damora Therapeutics, Inc.
DMRA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001800315
In the last 90 days, Damora Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 104 institutions reported holding it in 13F filings for Q2 2026, worth $1.67B in total; Viking Global Investors is the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:22 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 10, 2026 | – | – | Jan 6, 2023 | – |
| Operating expenses | $210.9M | $22.3M | $39.9M | $61.2M | $52.2M |
| Research and development | $26.9M | $6.40M | $23.8M | $48.2M | $38.5M |
| Selling, general and administrative | $9.69M | $10.5M | $12.7M | $13.0M | $13.7M |
| Operating income | -$210.9M | -$22.3M | -$39.9M | -$61.2M | -$52.2M |
| Income tax | $50.0K | $41.0K | $0 | $0 | $0 |
| Net income | -$209.8M | -$21.4M | -$38.3M | -$61.6M | -$51.8M |
| EPS, basic | $3.98 | $-18.53 | $-1.44 | $-2.43 | – |
| EPS, diluted | $3.98 | $-18.53 | $-1.44 | $-2.43 | – |
| Weighted shares, basic | 1.36M | 1.16M | 26.6M | 25.4M | – |
| Weighted shares, diluted | 1.36M | 1.16M | 26.6M | 25.4M | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 10, 2026 | – | – | Jan 6, 2023 | – |
| Cash and equivalents | $257.6M | $14.2M | $21.5M | $32.8M | $62.6M |
| Short-term investments | – | – | $11.7M | $27.4M | $37.6M |
| Total current assets | $260.4M | $16.8M | $36.8M | $63.9M | $110.1M |
| Property, plant and equipment | $36.0K | $57.0K | $78.0K | $357.0K | $203.0K |
| Total assets | $260.5M | $17.1M | $38.2M | $73.2M | $122.2M |
| Accounts payable | $444.0K | $377.0K | $1.70M | $3.35M | $1.53M |
| Total current liabilities | $20.1M | $1.20M | $5.83M | $11.1M | $4.54M |
| Total liabilities | $20.1M | $1.30M | $5.90M | $11.4M | $4.99M |
| Shareholders' equity | $240.4M | $15.8M | $32.3M | $61.8M | $117.2M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 10, 2026 | – | – | Jan 6, 2023 | – |
| Operating cash flow | -$6.73M | -$18.6M | -$36.9M | -$42.9M | -$52.3M |
| Capital expenditures | – | – | – | $196.0K | $223.0K |
| Free cash flow | – | – | – | -$43.1M | -$52.5M |
| Stock-based compensation | $998.0K | $3.24M | $5.43M | $5.57M | $4.48M |
| Investing cash flow | -$17.4M | $11.7M | $22.3M | $12.4M | -$48.0M |
| Financing cash flow | $266.8M | – | $2.88M | $507.0K | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 2, 2026 | 61.9M | +4,564.3% | SEC |
| Aug 7, 2026 | 61.7M | +4,560.8% | SEC |
| May 11, 2026 | 61.6M | +4,554.8% | SEC |
| Mar 17, 2026 | 60.3M | +4,460.3% | SEC |
| Nov 3, 2025 | 1.33M | +0.8% | SEC |
| Aug 1, 2025 | 1.32M | −95.1% | SEC |
| May 5, 2025 | 1.32M | −95.1% | SEC |
| Mar 14, 2025 | 1.32M | −95.1% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-25 in Q3 2024.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.